RxDoctor Payments Data

Gregory Kazmierski

Adult Health · Gainesville, FLNPI 1295715183

Payments from drug & device makers

$3,085in general payments, 2019–2025

Across 85 payments — averaging $36.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Amgen$348
  • AstraZeneca$255
  • E.r. Squibb & Sons, L.L.C.$231
  • Novartis$195
  • Boehringer Ingelheim$185
  • plus $640 from 12 others

What the payments were for

  • Travel & lodging$86628%
  • Food & beverage$1,98964%
  • Education$2297%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,085 in reported general payments places this provider in the 80th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$73,360
Medicare patients
566
Services billed
755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$263,291
EntrestoSacubitril/Valsartan69$88,469
XareltoRivaroxaban72$58,269
Repatha SureclickEvolocumab59$58,239
JardianceEmpagliflozin45$46,205
Repatha PushtronexEvolocumab21$14,550
FarxigaDapagliflozin Propanediol17$9,875
Metoprolol Succinate224$2,672
PradaxaDabigatran Etexilate Mesylate11$2,020
Atorvastatin Calcium214$2,017
Flecainide Acetate63$1,876
Diltiazem 12hr ErDiltiazem Hcl13$1,778
ClopidogrelClopidogrel Bisulfate140$1,670
Valsartan70$1,639
Diltiazem 24hr Er (Cd)Diltiazem Hcl75$1,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$142$263,291239 claims
NovartisEntresto$195$88,46969 claims
Johnson & JohnsonXarelto$32$58,26972 claims
Boehringer IngelheimJardiance, Pradaxa$185$48,22556 claims
AstraZenecaFarxiga$255$9,87517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,237 adult health providers in Florida.

Other adult health in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →